What the buyer wrote
PACE (Pathways to Antimicrobial Clinical Efficacy) is a £30 million initiative supporting and funding early-stage innovation in medicines and diagnostics, aimed at tackling AMR. It was established in September 2023 and is a collaboration between Innovate UK (IUK), LifeArc, and Medicines Discovery Catapult (MDC) - three leaders in the UK's health innovation and research community. PACE brings together the funding, resources, and partnerships to help innovators progress their early-stage antimicrobial drug and diagnostics projects with greater speed, support and confidence - giving the best AMR innovations the greatest chance of success. PACE will create a path to value through 3 strategic goa…
Details
- What the buyer calls it
- PACE Interim Impact Report
- How they are buying
- Advertised, open to anyoneAny supplier could bid without being invited first.
- Type
- services
Who the buyer named
Ms Laura Hough was the named contact on this notice. Questions closed on 23 Dec 2025, 14:00 GMT.